Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Camphor monobromide is a synthetic derivative of camphor, chemically known as (1R,3S,4S)-3-bromo-1,7,7-trimethylbicyclo[2.2.1]heptan‑2‑one with the formula C₁₀H₁₅BrO and a molecular weight of approximately 231.13 g/mol[1][2][5]. It is classified as a small molecule and has been used experimentally in pharmaceutical preparations. Camphor derivatives are generally known for their topical analgesic and counterirritant properties; however, specific pharmacological actions or approved indications for camphor monobromide are not well documented in current medical literature[1]. It has appeared as an ingredient in combination topical products (e.g., with levomenthol and methyl salicylate) intended for external use such as oils or ointments[1]. The mechanism of action is presumed to be similar to that of other camphoric compounds—likely acting on cutaneous sensory nerves to produce local analgesia via counterirritation—but no direct mechanistic studies have been published.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on camphor monobromide.